This study was conducted to evaluate the efficacy and safety of rituximab and @entity1749 in relapsed or refractory indolent B cell @entity1893 ( @entity1893 ). Treatments consisted of rituximab 375  mg/m(2), i.v. on days 1, 8, 15, and 22 of cycle 1 and on day one of cycles 2-5, @entity1749 1.6  mg/m(2), given by intravenous injection (3-s to 5-s bolus) on days 1, 8, 15, and 22 of a maximum of five cycles. The primary end points were the overall survival (OS) and progression-free survival (PFS). Secondary endpoints included response rate (ORR; CR) and @entity137 . From January 2008 to December 2010, 60 successive @entity1 at Tianjin @entity5 department were enrolled in this study. All @entity1 were recurrent or refractory indolent B cell @entity1893 , including @entity706 grades 1-2 (n  =  35), small @entity1072 / @entity1072 (LL/CLL; n  =  16) and @entity1074 (n  =  9). The median follow-up time was 30  months (range 12-48). The overall response rate was 70.0  %, with a CR/CRu rate of 31.7  %. The 2-year OS and PFS of all @entity1 were 75.0 and 41.0  %, respectively. Grade 3-4 @entity1398 and @entity882 occurred in 10 and 3.3  % of @entity1 , respectively. Higher IPI and refractory disease were independently associated with worse survival and PFS. RB chemotherapy in @entity1 with refractory or relapsed indolent B cell @entity1893 was effective with low @entity137 .

Rituximab and @entity1749 (RB): a new effective regimen for refractory or relapsed XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity1893 :: ('MESH:D008228', 'Disease') :: ["non-Hodgkin's lymphoma", 'NHL'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'toxicities'] @entity706 :: ('MESH:D008223', 'Disease') :: ['follicular lymphoma'] @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer hospital lymphoma'] @entity1074 :: ('MESH:D018442', 'Disease') :: ['marginal zone lymphoma'] @entity1072 :: ('MESH:D015451', 'Disease') :: ['lymphocytic lymphoma', 'chronic lymphocytic leukemia'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia'] @entity1749 :: ('MESH:C400082', 'Chemical') :: ['bortezomib', 'Bortezomib']
@entity706 :: (MESH:D008223,Disease) :: ['indolent lymphomas']
